Oct 1 |
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
|
Sep 29 |
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
|
Sep 25 |
Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case
|
Sep 12 |
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
|
Sep 12 |
The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly
|
Sep 6 |
Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest 6.7% decline adds to one-year losses, institutional investors may consider drastic measures
|
Aug 14 |
Intellia Therapeutics, Inc. (NTLA): Pioneering Gene Editing Solutions for Health Advancements
|
Aug 10 |
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
|
Aug 9 |
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
|
Aug 9 |
3 Gene Editing Stocks with Potential to Transform Medicine
|